ArticleJournal of oral and maxillofacial pathology : JOMFP
Desmoglein 1 and 3 as potential markers of occult lymph node metastasis in oral cancer.
Article in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The majority of oral cancers are oral squamous cell carcinomas (OSCC). The successful management of OSCC depends on early detection, timely intervention, and prevention of distant metastasis. Metastasis is an important aspect of OSCC-related deaths. Diagnosis of cervical lymph node metastasis is an essential requirement for clinical staging and treatment and is now widely accepted as an important factor in the prognosis of OSCCs. Roles of desmosomal cadherins desmoglein 1 (DSG1) and desmoglein 3 (DSG3) have been extensively studied and DSG3 is known to be a squamous-specific protein marker that is expressed specifically in the positive lymph nodes, and hence a potential marker for detecting occult lymph nodes, however, no conclusive evidence is established. The objective of this study was to assess DSG1 and DSG3 as potential biomarkers of lymph node metastasis. Materials and Methods: A total of 50 archival lymph node blocks, both positive and negative neck nodes of the patients treated for OSCC, were used for the assessment of DSG1 and 3 expressions by immunohistochemistry (IHC) following their histopathological examination. The assessment of IHC staining was conducted by two independent maxillofacial pathologists as per the grading criteria in all the lymph node sections. Results: A total number of 88 nodes were assessed, of which 27 were positive on histopathological assessment. DSG1 and DSG3 positivity were noted and varied between 11.4-12.5% and between 20.5-22.7% of positive nodes, respectively, between the observers. Cronbach's alpha was calculated for interobserver reliability for positive identification of metastatic lymph nodes. Area under curve (AUC) values for DSG1 were 0.478 and 0.02 for DSG3, and not so statistically significant value for DSG1 was obtained ( Conclusion: Current study results do not confirm the roles of DSG1 and 3 as potential markers for occult lymph node metastasis, and hence, the reliability of their roles may require further studies along with other markers of lymph node metastasis. Even though overexpression of DSG3 and partial expression of DSG1 in OSCC is seen, further studies may be required to confirm them either as a diagnostic or prognostic marker which can be useful for future management in cases of radical neck dissections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.